Altogether, our data imply that loss of G0S2 expression in CML disrupts lipid homeostasis, particularly glycerophospholipid metabolism, resulting in a block of differentiation that renders cells resistant to TKI therapy (Figure 8). The gene discussed is G0S2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.